Your trusted source for investing success

Tag: genetic testing

Genetics Facts for Investors

Genetics Facts for Investors

Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.

NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.

Fourth Quarter 2016 Highlights:

140% increase in clinical genetic testing volume(1)
122% increase in consolidated revenue to $60.5 million
11% reduction in average cost per clinical genetic

Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca’s PARP Inhibitor, Olaparib

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx®  test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza (olaparib), AstraZeneca’s PARP inhibitor.

The high

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network